4 Tips to Protect Your 340B Program Benefits
As a covered entity, you must protect your 340B program from manufacturers attempting to reduce savings and eligibility. Here are […]
Blog, Maxor
Blog, Maxor, MaxorPlus
Cell and Gene Therapy
As the field of cell and gene therapy advances, new opportunities will emerge for healthcare stakeholders, including payers, providers, and
Blog
A day in the life: Callen-Lorde Pharmacy
It’s 8:30 am on a late September day at the Callen-Lorde pharmacy in the Chelsea neighborhood of Manhattan. Staff meet
Blog
Is your hospital still operating pharmacy as a cost center? Time to update that old approach.
As a pharmacist and executive pharmacy leader, I nodded in agreement when reading McKinsey & Company describe pharmacy services as
Blog
One size does not fit all: GLP-1 weight loss coverage options for three companies
In the United States, 39.6% of adults live with obesity.[1] Glucagon-like peptide-1 (GLP-1) agonists, often used to treat diabetes, heart
Blog, Maxor, Press Releases
New Research Reveals More Hospital and Health System C-Suites are Transforming Pharmacy Services in the Next 3-5 years
Leaders say they are turning the cost centers into revenue streams A newly released industry survey report from Maxor, a
Blog, Maxor
MaxorPlus Formulary Update: Biosimilars
We are changing our formulary list for 2025, moving to a biosimilar for a frequently prescribed medication, Humira®. This switch
Blog, Maxor
Nothing to cry about: Exploring the latest treatments for dry eye disease
Dry eye disease (DED) is a common medical condition, and according to the National Eye Institute, it affects about 16
Blog, Maxor, Press Releases
MaxorPlus Named Top Workplace for Fourth Year in a Row
Maxor proudly announces that its pharmacy benefit management division, MaxorPlus, has been honored with the Top Workplaces 2024 award by
Blog, Maxor
Drug Spotlight – July 2024
Introducing our Drug Pipeline Spotlight We’ve highlighted three groundbreaking drugs recently approved or pending approval from the FDA. Want to